U002 United States Cutaneous Lymphoma Consortium Session: Unraveling the Complexities of Cutaneous Lymphomas
DESCRIPTION
Join global leaders as they demystify cutaneous lymphomas utilizing an interactive multidisciplinary tumor board format, the session is designed for attendees to recognize the heterogeneity of cutaneous lymphoid neoplasms, gain essential tools to recognize early signs, avoid common diagnostic pitfalls, and distinguish mimickers. Hear what’s new in treatments, including skin-directed therapies, targeted agents, and game-changing management pearls. Reviewing real-life cases, experts will discuss lessons learned from each case, review appropriate staging evaluations and therapeutics that you can apply in your clinic—this is the cutaneous lymphoma session you don’t want to miss.
LEARNING OBJECTIVES
Recognize the clinical heterogeneity of cutaneous lymphomas and distinguish them from common mimickers to reduce diagnostic delays.
Apply current evidence and expert insights to optimize staging and integrate evolving systemic and skin-directed therapies into clinical practice.
Enhance diagnostic and therapeutic approaches in diverse patient populations, including those with skin of color and complex clinical presentations.
SCHEDULE
7:30 AM
Welcome and Introduction to Cutaneous T Cell Lymphoma
Sima Rozati, PhD, MD, FAAD
7:40 AM
The Impact of Cutaneous Lymphoma International Prognostic Index (CLIPI) in Advanced CTCL
Youn H. Kim, MD, FAAD
7:55 AM
Understanding 'The Atypical Lymphoid Infiltrate' on Pathology Reports
Alejandro Gru, MD
8:10 AM
The Impact of Large Cell Transformation(LCT) on CTCL Management
Auris Huen, PharmD, MD, FAAD
8:25 AM
Q&A
DIRECTOR
Sima Rozati, PhD, MD, FAAD
SPEAKERS
Alejandro Gru, MD
Auris Huen, PharmD, MD, FAAD
Youn H. Kim, MD, FAAD
DISCLOSURES
Alejandro Gru, MD
Blueprint Medicines – Advisory Board(Fees); Dren Bio – Consultant (1099 relationship)(Fees); Innate Pharma, S.A. – Investigator(Honoraria);
Auris Huen, PharmD, MD, FAAD
CRISPR Therapeutics – Investigator(Grants/Research Funding); Innate Pharma S.A. – Investigator(Grants/Research Funding); Kymera Therapeutics – Investigator(Grants/Research Funding); Kyowa Kirin – Consultant(Honoraria); Scitech Development – Investigator(Grants/Research Funding); Seattle Genetics – Investigator(Grants/Research Funding); Soligenix, Inc – Investigator(Grants/Research Funding);
Youn H. Kim, MD, FAAD
CRISPR Therapeutics – Investigator(Grants/Research Funding); Dren Bio, Inc – Investigator(Grants/Research Funding), Other(No Compensation Received); Innate Pharma S.A. – Other(No Compensation Received); Innate Pharma, S.A. – Investigator(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); LIBO Pharma Corp. – Advisory Board(Honoraria); ONO-Pharma – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Secura Bio – Advisory Board(Honoraria); Takeda Pharmaceuticals USA Inc – Speaker(Honoraria); Treeline – Investigator(Grants/Research Funding);
Sima Rozati, PhD, MD, FAAD
Kyowa Kirin – Consultant (1099 relationship)(Honoraria), Other(Grants/Research Funding); Secura Bio – Consultant (1099 relationship)(Honoraria); Therakos, Inc. – Consultant (1099 relationship)(Honoraria);